Skip to main content
Premium Trial:

Request an Annual Quote

IncellDx OncoTect IO Lung Kit

IncellDx has launched the CE-IVD marked OncoTect iO Lung kit, a flow cytometry based assay. The kit incorporates a non-enzymatic single cell tissue homogenization process, using incellPREP, for unfixed tumor biopsy samples, labels cell suspensions with antibodies to CD45, CD8, CD3, PD-L1, stained with a Cell Cycle Dye, and then analyzes samples via flow cytometry. This allows researchers to enumerate the immune and tumor cell populations, quantify the percent of cells expressing PD-L1, and quantify PD-L1 receptor expression across each cell type. The assay also quantifies tumor infiltrating lymphocytes and quantification of PD-L1 expression at various stages of the tumor cell cycle.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.